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HBSS, Hanks' balanced salt solution
Profound immaturities in neonatal hematopoiesis predispose the newborn to significant cytopenias. Specifically, during overwhelming bacterial sepsis, the newborn is susceptible to a high incidence of thrombocytopenia and neutropenia (1-5). Decreased total body neutrophil storage pools, reduced total body myeloid progenitor pools (CFU-GM), and maximal myeloid progenitor proliferative rates have been previously demonstrated in newborn rats versus adult animals (1-4).
Human IL-6, first purified to homogeneity from the HTLV 11-transformed T cell line TCL/NA 1, has been noted to stimulate pluripotent hematopoietic stem cells and to act synergistically with IL-3 in the stimulation of multilineage hematopoietic blast colonies (6) (7) (8) . G-CSF, on the other hand, is a more myeloid lineage-specific CSF and has been demonstrated to stimulate myeloid proliferation and maturation and induce neutrophilia secondary to egress of neutrophil storage pool cells from bone marrow storage pool reserves (9-1 1).
IL-6 has recently been demonstrated to have significant in vitro effects on fetal myeloid progenitor proliferation (12) . We have previously demonstrated that both single-pulse administration of rhG-CSF and a prolonged 7-d administration in newborn rats result in a significant increase in peripheral neutrophilia, modulation of myeloid proliferation, and reduction in morbidity after experimental group B streptococcal sepsis (13) . In the present study, we investigated the modulation of in vivo neonatal hematopoiesis in the newborn rat by sequential administration of a nonlineage class I CSF such as IL-6 with a more lineagespecific class I1 CSF, G-CSF.
MATERIALS AND METHODS
G-CSF. RhG-CSF, kindly provided by Jeffrey Andresen, Amgen Laboratories, Thousand Oaks, CA, was prepared from an Escherichia coli host by recombinant DNA techniques. RhG-CSF was prepared to >95% purity before formulation in 0.025% human serum albumin. SDS-PAGE was used to confirm the purity of the growth factor by the appearance of a single protein band. Biologic activity of 2 x 10' units/mg was determined by granulocyte colony formation (CFU-G) on human nonadherent bone marrow cells in semisolid media. The Limulus amebocyte lysate assay (Sigma Chemical Co., St. Louis, MO) was used to demonstrate the absence of measurable endotoxin. The lower limits of detection of endotoxin using this assay were 0.05-0.1 endotoxin units/mL. Purified G-CSF was used at a dose of 5 pg/ kg/d by dilution with PBS, pH 7.4. QuantlJication of circulating and storage neutrophils. Blood samples were obtained by nicking the jugular vein or foot pad with a sterile needle and collecting 10 pL of free flowing blood. Total blood cell counts including platelets and hematocrit levels were electronically measured (Serano-Baker Diagnostics, Allentown, PA). Blood smears were prepared and stained with Wright stain, and a 100-200 cell differential was performed. Absolute neutrophil counts were determined by the multiplication of the nucleated cell count by the percentage of neutrophils in the differentials. Neutrophil bone marrow pools were determined by the method of Christensen et al. (4) . Briefly, neonate femurs were aseptically removed on d 14 and the contents were flushed into a known quantity of HBSS (Gibco Laboratories, Grand Island, NY). Livers and spleens were also removed on d 14 in a similar manner and finely minced in a known quantity of HBSS. Electronic cell counts were performed on the bone marrow, and a 500-cell differential count was obtained on Wright-stained cytospin preparations. CFU-GM concentration. Bone marrow and liver/spleen cells were collected as described above. Cells were then suspended in alpha media (Gibco Laboratories) with 1.1 % methylcellulose (Teny Fox Laboratories, Vancouver, BC), 30% vol/vol FCS (Hyclone Laboratories, Logan, UT), 10% BSA (Sigma Chemical Co.), 14.3 x M mercaptoethanol, 0.01 % vol/vol murine spleen cell conditioned medium (PWM-SCCM; Terry Fox Laboratories), and 1 U/mL erythropoietin (Amgen, Thousand Oaks, CA). Penicillin (100 000 U/L) and streptomycin (100 mg/L) were also added. Cell suspensions were plated in triplicate in 10-x 35-mm tissue culture dishes (Nunc, Roskilde, Denmark) and incubated at 5% C02, 37"C, in a high humidity atmosphere. Cultures were evaluated at 14 d with aggregates of >50 cells considered "colonies." Colonies were plucked at random, placed on a slide, and stained, and lineage specificity was confirmed.
IL-6 AND G-CSF EFFECT NEWBORN HEMATOPOIESIS
CFU proliferative rate. Proliferative rates of CFU-GM were evaluated by the thymidine suicide method of Christensen et al. aliquot was added 0.34 pg nonradioactive thymidine in a volume of 0.1 mL. The other aliquot received 0.34 pg methyl-3H-thymidine containing 0.1 mCi (sp act 75 Ci/mmol; ICN Radiochemicals, Irvine, CA). The tubes were incubated for 20 min at 37°C and were agitated every 5 min. Thymidine uptake was halted by adding 30 mL of ice cold a-minimum essential medium with 5% FCS and 100 pg/mL nonradioactive thymidine. The cell suspensions were then centrifuged and washed twice with the aminimum essential medium/FCS/thymidine media. Cells were then added in the same 1.1 % methylcellulose/alpha media described above. Colonies were allowed to develop for 14 d in a 5% COl incubator at 37"C, and thymidine suicide rate was determined by subtracting the average number of colonies formed per plate by cells exposed to 3H-thymidine from the average number of colonies per plate formed by cells exposed to nonradioactive thymidine and dividing by the average colonies per plate from cells exposed to nonradioactive thymidine.
Statistical analysis. All results are expressed as mean values +
SEM of eight to 15 animals, or three to five replicates of blood or bone marrow samples. The probability of significant differences when comparing two treated groups was determined with the use of the unpaired t test, and the probability of significant differences when examining multiple treatments was determined by using the analysis of variance followed by the Student-Newman-Keuls multiple range tests to define the unique subsets within the study. Statistical analyses were performed using the Biostat I statistical program (Sigma Soft, Placentia, CA) for the IBM personal computer. p values < 0.05 are considered significant.
RESULTS
Peripheral blood counts including hematocrit, white cell count, differential, and platelet count were determined on d 1, 3, 6, 8, 10, and 13 after intraperitoneal administration of rhIL-6 alone, rhIL-6 and rhG-CSF, or PBS/BSA control. During the 1st wk of administration, there was no significant difference in the peripheral platelet count between treatment groups. However, during the 2nd wk of administration, it became apparent that rhIL-6 significantly increased the peripheral platelet count over that of control animals (PBS/BSA) (Fig. 1) . The d-13 platelet count in the rhIL-6-treated animals was 980 + 42 x lo3 versus 716 + 23 x lo3 mm3 in the control animals ( p < 0.001). There was, however, no significant enhancement in those animals pretreated for 7 d with rhIL-6 followed by 7 d of rhG-CSF therapy versus 14 d of rhIL-6 alone (Fig. 1) . Fourteen d of rhG-CSF had no effect on the platelet count (data not shown).
There was a mild decrease in the circulating hematocrit in all groups of treated animals, although there was no statistical difference between the rhIL-6, rhG-CSF, or control group animals [hematocrit: (d 7 rhIL-6, 29.3 + 0.6%; rhG-CSF, 27.9 f. 0.8%; PBS/BSA, 27.5 + 0.8%; d 14 rhIL-6, 25.6 + 0.3%; rhG-CSF, 26.0 + 0.6%; PBS/BSA, 25.9 + 0.7%) ( p = NS)]. Additionally, there was no evidence of hemolysis on the peripheral smears from any of the treatment groups.
We also sought to determine whether there were any differences in the myeloid response between the different cytokine treatment arms. The absolute neutrophil count was calculated in each of the treatment groups. There was a significant difference between single and sequential cytokine therapy. In the single cytokine therapy, rhIL-6 alone failed to induce any significant increase in the circulating neutrophil count during the 14 d of administration compared with controls (PBS/BSA) (Fig. 2) . RhG-CSF, however, as expected, induced a pronounced neutro- (Figs. 2 and 3) .
On d 14 of this experimental study, animals were killed, and neutrophil storage and proliferative pools were determined from aseptically surgically removed femurs, livers, and spleens. There was a significant increase in the bone marrow neutrophil storage pool (polymorphonuclear cells + band + metamyelocytes) in the animals pretreated with rhIL-6 for 7 d followed by 7 d of rhG-CSF compared with animals pretreated with control PBS/BSA for 7 d followed by rhG-CSF ( p < 0.005) (Fig. 4) . However, 14 d of single-agent rhG-CSF therapy induced the most significant increase in the bone marrow neutrophil storage pool (p < 0.002).
Single-agent therapy with only rhIL-6 failed to induce a signifi- significant additive effect over that of any of the other treatment arms ( p < 0.01) (Fig. 5 ). RhIL-6 alone had no significant effect on CFU-GM production. Additionally, sequential therapy of 7 d of rhIL-6 followed by 7 d of rhG-CSF significantly increased the liver/spleen CFU-GM pools compared with 14 d of rhG-CSF and the other treatment groups ( p < 0.008) (Fig. 6) . CFU-GM proliferative rates were also determined from the bone marrow and liver and spleen CFU-GM colonies. There was, however, no significant difference in the CFU-GM proliferative rate among cytokine-treated groups. (Fig. 4) .
The neutrophil proliferative pool (blasts + promyelocytes + myelocytes), however, was not significantly different between treatment groups.
Bone marrow myeloid proliferative pools (CFU-GM) were also determined on d 14 after 14 d of cytokine administration. RhG-CSF induced a similar increase in the bone marrow CFU-G M as PBS/BSA/G-CSF and PBS/BSA alone. The sequential combination of rhIL-6 for 7 d followed by rhG-CSF had a mark finding in overwhelming bacterial sepsis in the human newborn and has traditionally been associated with a poor outcome (14, 15) . Future optimal therapy of neonatal sepsis or optimal prophylaxis may require adjuvant immunologic therapy to maintain adequate circulating numbers and qualitatively normal mature effector neutrophils.
IL-6 appears to act as a class I CSF, increasing early pluripotent blast cell colony formation with very little effect on mature progenitor proliferation (16) . IL-6 has additionally been demonstrated to synergistically increase pluripotent bone marrow progenitor cells with IL-3 (8, 16 ). IL-6 and IL-3 also appear to svnergisticallv stimulate purified human MY 10 (CD34+) bone --marrow progenitor cells 117). The synergism of IL-6 and IL-3 suggests that IL-6 may be acting on the induction of noncycling (GO) progenitor cells and may induce maturation into more committed lineage-specific progenitor activity. In vitro stimulation with rhIL-6 and cord peripheral blood and adult marrow progenitor cells suggests that rhIL-6 may support clonogenic maturation of multilineages, including CFU-GM, burst forming unit-erythorid, and colony forming unit-mixed colonies (12) .
G-CSF is a more lineage-specific CSF. In serum-free cultures, G-CSF induces CFU-G formation but, in the presence of accessory cells or serum, may additionally support the formation of
